Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients

References

• Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363, 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am. J. Cardiol.96, 61–68 (2005).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352, 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trail–Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomised controlled trial. Lancet366, 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA292, 2217–2225 (2004).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350, 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo–Scandinavian Cardiac Outcomes Trail-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet361, 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Sever P, Dahlöf B, Poulter N et al. Potential synergy between lipid-lowering and blood-pressure lowering in the Anglo–Scandinavian Cardiac Outcomes Trial. Eur. Heart J.27, 2982–2988 (2006).
   PubMed Web of Science ®Google Scholar
• Caduet®. Package insert. Pfizer Inc., NY, USA.
   Google Scholar
• Chung M, Calcagni A, Glue P, Bramson C. Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J. Clin. Pharmacol.46, 1030–1037 (2006).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA291, 1071–1080 (2004).
   PubMed Web of Science ®Google Scholar
• Norvasc®. Package insert. Pfizer Inc., NY, USA.
   Google Scholar
• Lipitor®. Package insert. Pfizer Inc., NY, USA.
   Google Scholar
• Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care23, 72–78 (2000).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Sipahi I et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am. J. Cardiol.97, 1553–1557 (2006).
   PubMed Web of Science ®Google Scholar
• Schoenhagen P, Tuzcu EM, Apperson-Hansen C et al. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation113, 2826–2834 (2006).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation98, 839–844 (1998).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Wilson DJ, Neutel J et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am. J. Hypertens.22, 137–144 (2009).
   PubMed Web of Science ®Google Scholar
• Cohn JN. Pathophysiologic and prognostic implications of measuring arterial compliance in hypertensive disease. Prog. Cardiovasc. Dis.41, 441–450 (1999).
   PubMed Web of Science ®Google Scholar
• Fogari R, Derosa G, Lazzari P et al. Effect of amlodipine–atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am. J. Hypertens.17(9), 823–827 (2004).
   PubMed Web of Science ®Google Scholar
• Fogari R, Preti P, Zoppi A et al. Effects of amlodipine–atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur. J. Clin. Pharmacol.62(10), 817–822 (2006).
   PubMed Web of Science ®Google Scholar
• Erdine S, Ro YM, Tse HF et al. Single-pill amlodipine–atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J. Hum. Hypertens.23(3), 196–210 (2009).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Flack JM, Victor R, Watson K et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin. Proc.83(1), 35–45 (2008).
   PubMed Web of Science ®Google Scholar
• Neutel JM, Bestermann MH, Dyess EM et al. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J. Clin. Hypertens.11(1), 22–30 (2009).
   PubMed Web of Science ®Google Scholar
• Preston RA, Harvey P, Herfert O et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J. Clin. Pharmacol.47(12), 1555–1569 (2007).
   PubMed Web of Science ®Google Scholar
• Ge CJ, Lu SZ, Chen YD, Wu XF, Hu SJ, Ji Y. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart. Vessels23(2), 91–95 (2008).
   PubMed Web of Science ®Google Scholar
• Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension47, 195–202 (2006).
   PubMed Web of Science ®Google Scholar
• Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J. Biol. Chem.266, 8604–8608 (1991).
   PubMed Web of Science ®Google Scholar
• Khosla UM, Zharikov S, Finch JL et al. Hyperuricemia induces endothelial dysfunction. Kidney Int.67, 1739–1742 (2005).
   PubMed Web of Science ®Google Scholar
• Martín-Ventura JL, Muñoz-Garcia B, Blanco-Colio LM et al. Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney Int. Suppl.111, S71–S74 (2008).
   PubMedGoogle Scholar
• Gilani M, Kaiser DR, Bratteli CW et al. Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertension. J. Am. Soc. Hypertens.1, 45–55 (2007).
   PubMed Web of Science ®Google Scholar
• Grey E, Bratteli C, Glasser SP et al. Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am. J. Hypertens.16, 265–269 (2003).
   PubMed Web of Science ®Google Scholar
• McVeigh GE, Bratteli CW, Morgan DJ et al. Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis: aging and arterial compliance. Hypertension33, 1392–1398 (1999).
   PubMed Web of Science ®Google Scholar
• Sugiyama M, Ohashi M, Takase H, Sato K, Ueda R, Dohi Y. Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels20, 133–136 (2005).
   PubMed Web of Science ®Google Scholar
• Lijnen HR, Collen D. Endothelium in hemostasis and thrombosis. Prog. Cardiovasc. Dis.22(Suppl. 4), S1–S14 (1993).
   Google Scholar
• Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J. Cardiovasc. Pharmacol.22(Suppl. 4), S1–S14 (1993).
   PubMed Web of Science ®Google Scholar
• Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med.114, 345–352 (1991).
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parker S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med.120, 713–719 (2007).
   PubMed Web of Science ®Google Scholar